Figure 2.

Chimeric antigen receptor (CAR) T cell trials for brain tumors vs other solid tumors. Clinical trial count in the United States evaluating CAR T cell therapy for solid tumors as of April 2019. As graphically represented, the largest number of CAR T cell trials for solid tumors is for brain tumors, which include trials for glioblastoma and other malignant gliomas (n = 12), as well as brain metastases (n = 1). Listed trials include those that are pending activation, enrolling patients, and completed